Barclays
SWAV

Barclays’s Shockwave Medical, Inc. Common Stock SWAV Stock Holding History

Barclays’s Portfolio SWAV Stock Details SWAV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-398
Closed -$2.2K – 5588
2024
Q2 		$2.2K Sell
398
-179,661
-100% -$59.1M ﹤0.01% 4634
2024
Q1 		$58.6M Sell
180,059
-69,156
-28% -$17M 0.02% 558
2023
Q4 		$47.5M Buy
249,215
+95,574
+62% +$18.1M 0.02% 695
2023
Q3 		$30.6M Buy
153,641
+101,557
+195% +$24M 0.02% 640
2023
Q2 		$14.9M Buy
52,084
+5,301
+11% +$1.47M 0.01% 827
2023
Q1 		$10.1M Buy
46,783
+7,690
+20% +$1.5M ﹤0.01% 1151
2022
Q4 		$8.04M Buy
39,093
+31,192
+395% +$7.89M ﹤0.01% 1322
2022
Q3 		$2.2M Buy
7,901
+4,649
+143% +$1.18M ﹤0.01% 1688
2022
Q2 		$621K Sell
3,252
-5,170
-61% -$913K ﹤0.01% 2707
2022
Q1 		$1.75M Sell
8,422
-64,466
-88% -$10.6M ﹤0.01% 1973
2021
Q4 		$13M Buy
72,888
+26,436
+57% +$5.21M ﹤0.01% 1135
2021
Q3 		$9.56M Sell
46,452
-188,969
-80% -$37.1M ﹤0.01% 1227
2021
Q2 		$44.7M Buy
235,421
+189,790
+416% +$31.1M 0.02% 568
2021
Q1 		$5.94M Buy
45,631
+1,338
+3% +$160K ﹤0.01% 1386
2020
Q4 		$4.6M Buy
44,293
+25,301
+133% +$2.19M ﹤0.01% 1567
2020
Q3 		$1.44M Sell
18,992
-8,938
-32% -$507K ﹤0.01% 2380
2020
Q2 		$1.32M Buy
27,930
+10,186
+57% +$420K ﹤0.01% 2497
2020
Q1 		$588K Sell
17,744
-10,712
-38% -$425K ﹤0.01% 3460
2019
Q4 		$1.25M Buy
28,456
+24,283
+582% +$897K ﹤0.01% 3469
2019
Q3 		$125K Sell
4,173
-264
-6% -$11.2K ﹤0.01% 5318
2019
Q2 		$253K Buy
+4,437
New +$215K ﹤0.01% 4901

Other funds holding SWAV

EI
Ethic Inc New York $6.39B AUM 29.64% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Barclays's SWAV Position: Q3 2024 in Review

Barclays sold out of Shockwave Medical, Inc. Common Stock (SWAV) in Q3 2024, closing a stake of 398 shares — an estimated $2.2K sold.

Barclays first reported a position in SWAV in Q2 2019 and held it in 21 quarters. The position peaked at $58.6M in Q1 2024. 2 funds tracked by Wall St. Rank hold SWAV as of Q3 2024.

  • Barclays reported no remaining Shockwave Medical, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Barclays sold 398 Shockwave Medical, Inc. Common Stock shares in Q3 2024, an estimated $2.2K.
  • Barclays first reported a position in Shockwave Medical, Inc. Common Stock in Q2 2019 and held it in 21 quarters.
  • Barclays's Shockwave Medical, Inc. Common Stock position peaked at $58.6M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Shockwave Medical, Inc. Common Stock as of Q3 2024.

Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.